4CMenB tied to modest gonorrhea protection in real-world study
Overview
A study found that the 4CMenB vaccine showed an effectiveness of 38.4% in reducing gonococcal notifications among adolescents in high-prevalence settings.
Background
Gonorrhea is a significant public health concern, particularly among adolescents, due to its potential complications such as pelvic inflammatory disease and infertility. The close genetic relationship between Neisseria gonorrhoeae and Neisseria meningitidis raises interest in the potential for meningococcal vaccines to provide cross-protection against gonorrhea.
Data Highlights
| Measure | Value |
|---|---|
| Vaccine Effectiveness (2 doses) | 38.4% (95% CI, 18.6%-53.4%) |
| Overall Meningococcal Carriage Prevalence | 4% to 6.2% |
| Odds Ratio for Carriage Increase | 1.68 (95% CI, 1.14-2.48) |
| Percentage of Fully Vaccinated Adolescents | 9.6% |
| Percentage Identifying as Aboriginal or Torres Strait Islander | 42.4% |
Key Findings
- The 4CMenB vaccine provides a two-dose effectiveness of 38.4% against gonorrhea.
- Vaccinated adolescents had lower gonococcal notifications compared to unvaccinated peers.
- Meningococcal carriage increased from 4% to 6.2% post-vaccination.
- Carriage of meningococci associated with disease remained stable.
- Limitations included lower-than-expected vaccine uptake and missing data in the carriage analysis.
Clinical Implications
Clinicians should continue to emphasize comprehensive screening and prevention practices, especially in high-prevalence populations.
Conclusion
The study indicates that the 4CMenB vaccine may provide modest protection against gonorrhea in adolescents.
Related Resources & Content
- Marshall H, Open Forum Infectious Diseases, 2023 -- 4CMenB tied to modest gonorrhea protection in real-world study
- The Journal of Infectious Diseases — Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection
- Open Forum Infectious Diseases — Exploring the Natural History of Gonorrhea and the Protective Role of 4CMenB: A Call for Further Research and Improved Data Collection
- MDSpire News — PrEP Use Linked to Higher Gonorrhea Rate
- International Journal of Infectious Diseases — Reassessing the Role of Meningococcal B Vaccination in Preventing Gonorrhoea Among Men Who Have Sex with Men
- Clinical Treatment of Gonorrhea | Gonorrhea | CDC
- Multidesign Study of 4CMenB Vaccine Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People | Open Forum Infectious Diseases | Oxford Academic
- Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study - PMC
- Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study | Open Forum Infectious Diseases | Oxford Academic
- Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO) - PMC
- Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection - PubMed
- National gonorrhoea vaccination programme using 4CMenB vaccine: frequently asked questions - GOV.UK
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
